The severity of thrombocytopenia and the level of activated platelets were reduced in the TBI mice receiving ANV-6L15. Circulating platelets that expressed CD62p (A) and those that expressed both CD62p and PS (B) (n = 9 mice per group, 1-way ANOVA). (C) Platelets formed a complex with BDEVs and its blockage by ANV-6L15 (n = 9 mice per group, one-way ANOVA). (D) Platelets formed a complex with exMT in the absence and presence of 1 µg/ml of ANV-6L15, as detected by image flow cytometry. Top panel: representative images of GFP-exMT-platelet complexes (scale bar, 5 µm). Bottom panel: summary of 12 independent experiments (Student t test). (E) Thrombin generation induced by 3.5 × 10³/µL of BDEVs in the presence of increasing concentrations of either ANV-6L15 or ANV. Graph: representative images. Insert: summary of 26 independent experiments (1-way ANOVA). (F) Clotting time induced by 6 × 10³/µL of BDEVs in the presence of either ANV-6L15 or ANV (n = 13 mice per group, 1-way ANOVA). To be consistent with other experiments, ANV-6L15 was compared with ANV by weight (µg/mL), not by molar concentrations. Because of a smaller molecular mass, the results suggest that ANV was even less efficacious than ANV-6L15 in blocking thrombin generation.